166 related articles for article (PubMed ID: 17008691)
1. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
O'Dwyer PJ; Catalano RB
J Clin Oncol; 2006 Oct; 24(28):4534-8. PubMed ID: 17008691
[No Abstract] [Full Text] [Related]
2. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
5. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
6. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
8. UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Kanekiyo S; Hazama S; Kondo H; Nagashima A; Eto R; Yoshida S; Shimizu R; Araki A; Yamamoto T; Uchiyama T; Yoshino S; Okayama N; Hinoda Y; Oka M
Anticancer Res; 2013 Aug; 33(8):3423-30. PubMed ID: 23898114
[TBL] [Abstract][Full Text] [Related]
9. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E
Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419
[TBL] [Abstract][Full Text] [Related]
10. UGT1A and irinotecan toxicity: keeping it in the family.
Hoskins JM; McLeod HL
J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
[No Abstract] [Full Text] [Related]
11. [Relationship between UGT1A and irinotecan-related toxicity].
Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249
[No Abstract] [Full Text] [Related]
12. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S; Blanchard RL
Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
[TBL] [Abstract][Full Text] [Related]
13. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
Ratain MJ
Clin Cancer Res; 2006 Mar; 12(6):1658-60. PubMed ID: 16551845
[No Abstract] [Full Text] [Related]
14. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Perera MA; Innocenti F; Ratain MJ
Pharmacotherapy; 2008 Jun; 28(6):755-68. PubMed ID: 18503403
[TBL] [Abstract][Full Text] [Related]
16. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
[TBL] [Abstract][Full Text] [Related]
17. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan pharmacogenetics: influence of pharmacodynamic genes.
Hoskins JM; Marcuello E; Altes A; Marsh S; Maxwell T; Van Booven DJ; Paré L; Culverhouse R; McLeod HL; Baiget M
Clin Cancer Res; 2008 Mar; 14(6):1788-96. PubMed ID: 18347181
[TBL] [Abstract][Full Text] [Related]
19. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).
Pacheco PR; Brilhante MJ; Ballart C; Sigalat F; Polena H; Cabral R; Branco CC; Mota-Vieira L
Mol Diagn Ther; 2009; 13(4):261-8. PubMed ID: 19712005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
